Screener / SEC EDGAR /CIK 0001388658 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

iRhythm Holdings, Inc. IRTC

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers IRTC said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $870.00M to $880.00M release Feb 19, 2026
Raised $875.00M to $885.00M release Apr 30, 2026
Raised $880.00M to $890.00M release Aug 6, 2026
Raised $890.00M to $895.00M release Nov 5, 2026
– Not reported yet
The company's words
For the full year 2026, iRhythm expects revenue of $870 million to $880 million and adjusted EBITDA margin of 11.5% to 12.5%, reflecting continued volume-led growth, gross margin expansion, and operating leverage while maintaining disciplined investment in innovation and market expansion. release Feb 19, 2026
Increased fiscal year 2026 revenue guidance to $875 million to $885 million and adjusted EBITDA margin to 12.0% to 13.0% release Apr 30, 2026
Increased fiscal year 2026 revenue guidance to $880 million to $890 million and adjusted EBITDA margin guidance to 13.0% to 14.0% release Aug 6, 2026
Increased fiscal year 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0% release Nov 5, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $675.00M to $685.00M release Feb 20, 2025
Raised $720.00M to $730.00M release Jul 31, 2025
Raised $735.00M to $740.00M release Oct 30, 2025
$747.14M
10-K filed 2026-02-19
Above the range
The company's words
iRhythm projects revenue for the full year 2025 between $675 million to $685 million. release Feb 20, 2025
iRhythm projects revenue for the full year 2025 between $720 million to $730 million. release Jul 31, 2025
iRhythm projects revenue for the full year 2025 between $735 million to $740 million. release Oct 30, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $578.00M to $588.00M release May 2, 2024
$591.84M
10-K filed 2025-02-20
Above the range
The company's words
Increased fiscal year 2024 revenue guidance to a range of $578 million to $588 million release May 2, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (11 releases since 2024-02-22), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IRTC/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.